Daily Brief Health Care: Seed Co Ltd/Tokyo, Aspen Pharmacare Holdings, Seers, Innovent Biologics, Mayne Pharma, Tenax Therapeutics , AgeX Therapeutics , D.Western Therapeutics Institute Inc., Generate Biomedicines, Lakewood-Amedex Biotherapeutics and more

• Seed Co Ltd/Tokyo (7743 JP) announced a tender offer from Luxshare Precision Industry (2475 HK) at JPY795, a 48.6% premium to the last close of JPY535.  
• Despite the lack of an auction, the offer is above the midpoint of the IFA’s DCF valuation range and is attractive compared to historical trading ranges.
• The required minority acceptance rate to meet the lower limit is not onerous. This is a done deal. The offer closes on 13 October.  

• On Monday night, the price snapshot was taken for the JSE September 2026 rebalance. APN is expected to enter the Top 40 index with WHL exiting, MTM is expected to enter the FINDI, with WHL falling out.
• There are no changes expected for the INDI, RESI and FINI indices.
• The JSE rebalance is scheduled for the closing auction on Friday 18th September.

• Seers (458870 KS) is a digital healthcare firm in Korea that specializes in wearable medical biosensors, artificial intelligence (AI)-driven clinical data analysis, and remote patient monitoring (RPM) platforms.
• Given the company’s surging sales and profit growth, I believe it deserves to trade at 20x P/E. 
• Assuming consensus net profit estimate of 86.8 billion won, a 20X P/E suggests market cap of 1.7 trillion won, representing 110% upside from current levels (about 44,000 won per share). 

• 1H26 represents another strong set of results (robust topline growth + operating leverage). Innovent unveiled a new 2030 revenue target RMB35-40bn, implying 16-20% 4-year CAGR (using our 2026E revenue estimates).
• 2H26/Early 2027 catalysts: 1) IBI363: pivotal data (melanoma) and PoC data (1L NSCLC, 1L GC) in ESMO; 2) IBI354: ovarian cancer data and NDA filing; 3) mazdutide: Glory-3 readout…
• 1H26 results call focus on: 1) growth drivers for 2030 revenue target, 2) 2H26 outlook, 3) key data readouts for 2H26/early 2027. See inside for P&L analysis and pipeline updates.

• Financial Architecture Inflation: Mayne Pharma’s reported gross margins and EBITDA are structurally inflated by its balance sheet treatment of the TherapeuticsMD (TXMD) royalties. Instead of flowing through the P&L as Cost of Goods Sold (COGS) or operating expenses, the 8% royalty payments to TXMD are treated as a reduction of the balance sheet’s AUD 336.0 million deferred consideration liability, shielding operating profits from true commercial costs.
• The Cosette Transaction Double-Bind: While the NSW Supreme Court ruled in Mayne’s favor in October 2025, declaring that Cosette did not validly terminate its AUD 672.0 million takeover bid on MAC grounds, the deal was ultimately killed by the Australian Treasurer (FIRB) on national-interest grounds in November 2025. Current litigation is now a damages battle, with Mayne accusing Cosette of intentionally sandbagging the FIRB process to walk away from a deteriorating asset base.
• DistributeRx Execution Risk: Launched in March 2026, the DistributeRx direct-to-patient model is an aggressive attempt to disintermediate the traditional U.S. payer-wholesaler value chain. While prescription volumes rose to 62,000 in its first full quarter, the strategy shifts commercial risk entirely onto Mayne’s balance sheet, requiring a major capital outlay for Adelaide Apothecary’s new Lexington facility to support a target capacity of 2.5 million annual prescriptions.

• Tenax Therapeutics, Inc. (NASDAQ:TENX) has become one of the more unusual biotechnology special situations of August.
• The company is developing oral levosimendan for pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, a difficult cardiovascular condition with no approved therapy specifically targeting this population.
• On August 10, the investment case appeared to break.

• Serina Therapeutics, Inc. is a clinical-stage biotechnology company developing wholly-owned drug product candidates for neurological diseases. Its POZ Platform™ technology improves polymeric drug conjugates.
• Serina Therapeutics received FDA IND clearance for SER-252 in January 2026 and dosed the first patient in its Phase 1b trial in February 2026.
• Management concluded substantial doubt exists about the Company’s ability to continue as a going concern within twelve months.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• D. Western Therapeutics Institute, Inc. (DWTI, hereafter the Company) announced its H1 FY2026/12 results after market close on August 13, 2026.
• For TissueBlue , the Company and licensee DORC are currently discussing detailed terms and conditions for extending their agreement in the US, where the patent remains in force.
• SIR believes that if the planned product launches proceed on schedule, expectations for the Company will rise further and be reflected in its share price.

• GENB’s 20.9% first-day decline was among 2026’s worst IPO debuts, but shares have since recovered sharply and moved above the $16 IPO price.
• GB-0895 remains the key value driver, with two global Phase 3 asthma studies advancing across 33 countries.
• Generate exited 2Q26 with $457.4 million of cash and expects funding to support its current operating plan into 1H28.

• On August 14, 2026, Lakewood-Amedex Biotherapeutics, Inc. (LABT) filed form 10-Q with financial results for the second quarter of 2026.
• Since we initiated coverage on June 23, 2026, Lakewood has continued preparations for the Phase 2a clinical trial of Nu-3 in infected diabetic foot ulcers.
• The study will evaluate 2%, 5%, and 10% concentrations of topical Nu-3 and is intended to provide proof-of-concept data supporting potential advancement into Phase 2b.